BlossomHill Therapeutics (BLSM) vs Crescent Biopharma (CBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BlossomHill Therapeutics is the larger company by market cap ($536.5 million vs $524.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLSM | CBIO |
|---|---|---|
| Share price | $16.88 | $14.12 |
| Market cap | $536.53M | $524.51M |
| 1-day change | +1.63% | +4.67% |
| YTD return | — | +19.06% |
| 1-year return | — | +17.08% |
| 5-year return | — | -92.87% |
| EPS (TTM) | $-4.70 | $-7.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.99 | $27.41 |
| 52-week low | $15.25 | $8.72 |
| Distance from 52-week high | -39.69% | -48.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +109.72% | +123.09% |
| Average volume | 261.23K | 399.18K |
| Shares outstanding | 31.78M | 37.14M |
| Employees | 69 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
BLSM vs CBIO FAQ
Which is bigger, BlossomHill Therapeutics or Crescent Biopharma?
BlossomHill Therapeutics (BLSM) is larger, with a market capitalization of $536.53M compared with $524.51M for Crescent Biopharma (CBIO).
Are BlossomHill Therapeutics and Crescent Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.